TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05763381

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation Therapy (PBMT)
Description: Participants will receive PBMT with the PBM device over the course of three consecutive weeks (three treatments per week). PBM treatments will take approximately 5-10 minutes to administer at each session. Specific treatment parameters will be based on measurements of calf, ankle, and foot using pre-calculated treatment tables; participants will receive 10 J/cm2, 25W output power, and the length of the treatment will be dependent on treatment area (size). PBMT will be administered by a trained member of the study team using the LightForce® XPi therapy laser, provided by LiteCure, LLC/DJO Global (New Castle, DE). The LightForce® XPi therapy laser is an FDA cleared device for the treatment of pain. The trained team members will use the Smart Hand Piece technology, which achieves effective treatments and improves dosing accuracy by assessing the operator's speed and providing real-time visual (red - amber - green light) and sensory feedback.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham-Photobiomodualtion Therapy (Sham-PBMT)
Description: Sham-PBM treatment time will be calculated in the same way as the PBM treatment group, with the time of treatment dependent on the size of the treatment area. The sham-PBMT will be administered by rolling the massage ball over the plantar surface of the foot and dorsal aspect of the calf in contact with the participants' skin. Because emission of photons at the selected treatment parameters may cause participants in the treatment group to feel warmth, the massage ball will be warmed in the sham-PBMT. The device will be turned on, so the red aiming beam will be visible, but the operator will not activate the switch to emit photons.
Study: NCT05025098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: For AML patients: Venetoclax will be administered orally once daily Days 1 through 28, of a 28-day cycle, with a designated dose of 400 mg daily after ramp up in Cycle 1. During Cycle 1 Days 1 - 3, the dose of Venetoclax will ramp up from 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Azacitidine (100 mg/m2) is given once daily following administration of venetoclax for 5 days of every cycle, starting on Day 1 of each cycle.~For MDS patients: Azacitidine (100 mg/m2) is given once daily for 5 days of every 28 day cycle, starting on day 1 of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: For AML patients: Venetoclax will be administered orally once daily Days 1 through 28, of a 28-day cycle, with a designated dose of 400 mg daily after ramp up in Cycle 1. During Cycle 1 Days 1 - 3, the dose of Venetoclax will ramp up from 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Azacitidine (100 mg/m2) is given once daily following administration of venetoclax for 5 days of every cycle, starting on Day 1 of each cycle.~For MDS patients: Azacitidine (100 mg/m2) is given once daily for 5 days of every 28 day cycle, starting on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precision therapy
Description: Precision therapy for both AML and MDS patients is standard therapy + tumor board determined precision therapy. The tumor board determined precision therapy can be all available drugs with a marketing authorization in Norway.
Study: NCT04717297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Management Remote Intervention
Description: First, the study pharmacist reviews the older adult's medication for potentially inappropriate medications. The pharmacist collaborates with the prescribing physician(s) to deprescribe as indicated. The pharmacist educates the older adult and OT on any changes that were made. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT provides training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered remotely.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Waitlist Control
Description: A trained research assistant will complete two attention control visits in the homes of participants. Visit will consist of semi-structured interview exploring the participant's life history.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Management In-Person Intervention
Description: Participants in the waitlist control will be offered the medication management intervention to be completed in person. If they consent, the study pharmacist will review their medication for potentially inappropriate medications. The pharmacist will collaborate with the prescribing physician(s) to deprescribe any inappropriate medication as indicated. The pharmacist will educate the older adult and OT on any changes. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants will receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT will provide training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered in person.
Study: NCT04902924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: repeated cold water therapy
Description: This information can be found the description of the experimental arm.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: repeated warm water therapy
Description: This information can be found the description of the experimental arm.

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: This information can be found the description of the experimental arm.
Study: NCT04929041

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT06418269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Play
Description: Children will be asked to fill in the Child Patient Identification Form, State Anxiety Scale in Children and Child Fear Scale 30 minutes before insulin treatment. Before the insulin treatment, the children in the experimental group will have their blood glucose measured and insulin administered on a doll using the therapeutic play method. The child will be told that the doll is hospitalized with a diagnosis of Type 1 diabetes and will be expected to assume the role of a nurse to administer insulin to the doll. Then, the steps of blood glucose measurement and insulin treatment (subcutaneous) will be explained to the child and the child will be asked to administer insulin to the baby. Within 10 minutes after subcutaneous insulin treatment, the child will be asked to fill out the State Anxiety Scale in Children and Child Fear Scale.
Study: NCT06634303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain cooling
Description: Brain cooling intervention in acute ischemic stroke patients post mechanical thrombectomy
Study: NCT05733221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Printed Model
Description: 3D Printed Model generated pre-operatively of the patients mandible.
Study: NCT05554081

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Peezy urine collection device
Description: use peezy collection to obtain urine sample

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Peezy urine collection device
Description: use peezy collection to obtain urine sample

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peezy urine collection device
Description: use peezy collection to obtain urine sample

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peezy urine collection device
Description: use peezy collection to obtain urine sample
Study: NCT06446856

Intervention type: DEVICE
Intervention: VR application
Description: The VR application consists of a software (Tree) developed as part of a research project at MIT and legally acquired via the HTC store Viveport. Duration of the VR application: approx. 5 min.

Intervention type: DEVICE
Intervention: VR application
Description: The VR application consists of a software (Tree) developed as part of a research project at MIT and legally acquired via the HTC store Viveport. Duration of the VR application: approx. 5 min.

Intervention type: DEVICE
Intervention: VR application
Description: The VR application consists of a software (Tree) developed as part of a research project at MIT and legally acquired via the HTC store Viveport. Duration of the VR application: approx. 5 min.
Study: NCT04964648

Intervention type: DEVICE
Intervention: shear wave elastography
Description: Shear wave elastography (SW-EG), a form of ultrasound elastography used in transabdominal ultrasonography, can measure tissue elasticity by generating shear waves inside the organ using the acoustic radiation force impulse (ARFI) The ultrasound machine monitors shear wave propagation and measures the velocity. The shear wave velocity, displayed in kilopascals (kPa) or meters per second

Intervention type: DEVICE
Intervention: shear wave elastography
Description: Shear wave elastography (SW-EG), a form of ultrasound elastography used in transabdominal ultrasonography, can measure tissue elasticity by generating shear waves inside the organ using the acoustic radiation force impulse (ARFI) The ultrasound machine monitors shear wave propagation and measures the velocity. The shear wave velocity, displayed in kilopascals (kPa) or meters per second

Intervention type: DEVICE
Intervention: shear wave elastography
Description: Shear wave elastography (SW-EG), a form of ultrasound elastography used in transabdominal ultrasonography, can measure tissue elasticity by generating shear waves inside the organ using the acoustic radiation force impulse (ARFI) The ultrasound machine monitors shear wave propagation and measures the velocity. The shear wave velocity, displayed in kilopascals (kPa) or meters per second
Study: NCT05384015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib is an oral, potent multiple receptor tyrosine kinase (RTK) i that selectively inhibits VEGF-driven VEGFR2 phosphorylation and suppressed proliferation and tube formation in human umbilical vein endothelial cell models. Antitumor activity of lenvatinib in vivo has been shown in numerous xenograft animals. These results suggest that lenvatinib may be a novel anticancer therapy through inhibition of angiogenesis and may be useful as either monotherapy or in combination with other anticancer drugs.~Part 1 (safety run-in) and Part 2:~The study intervention consists of:~Dose: 8 mg (induction) and 20 mg (maintenance) Dose Frequency: Once daily Dose formulation: Capsule Route of administration: Oral Treatment duration: 4 cycles (induction) and no treatment duration limit (maintenance).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).~Part 1 (safety run-in) and Part 2:~Dose: 200 mg Frequency: Day 1, Q3W Route: Intravenous Treatment Period: Up to 35 cycles or until reaching a discontinuation criterion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Standard first-line treatment for the vast majority of patients with SCLC, regardless of stage, involves combination chemotherapy with etoposide plus cisplatin or carboplatin.~Pharmacotherapeutic group: Cytostatics, plant alkaloids and other natural products, derived from podophyllotoxin. Mechanism of action :The main effect of etoposide appears to be in the late S and early G2 phase of the cell cycle, in mammalian cells.~Part 1 (safety run-in) and Part 2:~Dose: 100 mg/m2 Frequency: Day 1-3, Q3W Route: Intravenous Treatment Period: 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmacotherapeutic group: Other antineoplastic agents, platinum compounds.~Carboplatin, like cisplatin, binds to DNA to produce inter- and intra-strand cross-links cells exposed to carboplatin. DNA reactivity has been linked to cytotoxicity.~Part 1 (safety run-in) and Part 2:~Dose: AUC5 Frequency: Day 1, Q3W Route: Intravenous Treatment Period: 4 cycles
Study: NCT05628454

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound-guided transbronchial needle Slow-pull capillary sampling
Description: The slow-pull capillary technique was performed as follows: after identification and measurement of the target lymph node, a needle was used to puncture the lymph node with the stylet in place.At the same time, the stylet was slowly and continuously pulled to create weak negative pressure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound-guided transbronchial needle aspiration
Description: The operation steps are the same as above, but the negative pressure device of 10ml syringe is connected behind the puncture needle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound-guided transbronchial needle capillary sampling
Description: The operation steps are the same as above, but there is no negative pressure device behind the puncture needle
Study: NCT05964244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vela Investigational Mask
Description: Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nivairo Standard Mask
Description: Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy.
Study: NCT05118464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task training
Description: Dual-task training includes simultaneous execution of motor and cognitive tasks. The motor tasks in this study will be walking, going up and downstairs, turning, throwing, and holding a ball. Cognitive tasks will be an n-back test, verbal fluency, remembering sequences of numbers, and performing simple summing.
Study: NCT04433572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temsirolimus
Description: 0.1 mg/mL temsirolimus, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Saline placebo, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.
Study: NCT05856006

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: upper trapezius stretching plus neck isometrics
Description: upper trapezius stretching plus neck isometrics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upper trapezius stretching with mid-lower trapezius strengthening exercises plus neck isometrics
Description: Mid-Lower Trapezius strengthening exercise includes:~1. Latissimus pull down~2. Prone V- raise~3. Modified Prone Cobra
Study: NCT06100731

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (FC6, 10-10 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/ out at the beginning and end of the 15-minutes of stimulation over the course of 15 seconds.
Study: NCT05430191

Intervention type: OTHER
Intervention: Cascade Screening
Description: FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.

Intervention type: OTHER
Intervention: Cascade Screening
Description: FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.
Study: NCT04981366

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplement
Description: 40g of whey protein in the breakfast;

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: isocaloric supplement
Description: 42g of isocaloric supplement in the breakfast;
Study: NCT06390696

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Microbial intervention
Description: Children in microbial intervention arm receive an indoor sandbox containing play sand enriched with organic leaf compost, moss and humus substances. Families also receive an indoor cultivation set including growing box, seeds, spray bottle, plant lamp and microbe rich growing medium containing organic leaf compost, moss, biochar and humus substances.
Study: NCT06100731

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (FC6, 10-10 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/ out at the beginning and end of the 15-minutes of stimulation over the course of 15 seconds.
Study: NCT06125210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: early bedside rehabilitation
Description: ① electrical diaphragm stimulation, ② electrical muscle stimulation, ③ passive limb movement, ④ respiratory rehabilitation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutrition program
Description: (1) nutrition department consultation, (2) MDT to develop individualized nutritional pathways, nutrient formulations and use methods, and achieve the target nutritional level within 2 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tracheotomy
Description: early tracheotomy for special diseases (e.g central nervous system diseases) receiving mechanical ventilation 14-21 days recommended tracheotomy
Study: NCT05132504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be initiated starting with the Cycle 2 Day 1 and will be administered every 6 weeks with a max amount of 9 cycles throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: Once eligibility has been confirmed and the patient has been registered to the study, the patient will begin induction modified FOLFIRINOX (Oxaliplatin, Leucovorin, Irinotecan, 5-Fluorouracil) chemotherapy treatment. Each cycle is 14 days; a total of six cycles will be administered. Patients will receive growth factor support at the discretion of treating physician.
Study: NCT05636397

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Description: Citrulline is a nonessential amino acid made in the small intestine, occurs naturally in the body, and is believed to help reduce inflammation.L-CIT is a part of the urea cycle, produced as a by-product along with nitric oxide (NO).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Description: Citrulline is a nonessential amino acid made in the small intestine, occurs naturally in the body, and is believed to help reduce inflammation.L-CIT is a part of the urea cycle, produced as a by-product along with nitric oxide (NO).
Study: NCT05258903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ulnar artery cannulation
Description: Ulnar artery will be cannulated under USG guidance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial artery cannulation
Description: Radial artery will be cannulated under USG guidance
Study: NCT05763901

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical tests and motor control evaluation using Inertial Measurement Units
Description: Each patient is evaluated using clinical tests (Movement ABC2, Test of Motor Competence), a screening questionnaire (DCD-Q), and wearable Inertial Measurement Units to assess balance and motor control during a Natural Walking and Tandem Walking test.
Study: NCT05241860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy Discontinuation
Description: Stop hormonal medications (Abiraterone, Enzalutamide, Apalutamide, Leuprolide, Goserelin, Degarelix, Relugolix)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-Up
Description: Undergo follow-up

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05524116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Exercise program
Description: In this 8-week intervention, components of Mindful Based Stress Reduction Program will be integrated with strengthening and neuromuscular exercises recommended for knee osteoarthritis. The goal of this program is to train participants how to be mindful during their exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: In this 8-week intervention, participants will be given recommended strengthening and neuromuscular exercises for knee osteoarthritis. Participants in both the intervention and control group will receive these exercises.
Study: NCT06633809

Intervention type: OTHER
Intervention: Immediate endovascular therapy
Description: The best medical therapy includes intravenous fibrinolysis, anticoagulants or antiplatelet, but NOT any immediate endovascular therapies.